Practical Pediatric Hematology

Pediatric hematology is a specialized branch of medicine focused on blood disorders in children. Unlike adult hematology, pediatric hematology must account for the unique physiological characteristics of developing children, whose blood and immune systems are continually maturing. This field encompasses a wide range of conditions from common anemias to complex inherited disorders affecting blood clotting and cell production.

Understanding Pediatric Hematological Development

Children's blood values and hematopoietic (blood-forming) systems differ significantly from adults. These developmental variations are essential considerations when evaluating blood tests and making diagnoses. Key developmental milestones include:

During fetal life, hematopoiesis occurs in multiple sites including yolk sac, liver, spleen, and finally bone marrow. At birth, the hematopoietic system is largely distributed throughout the entire skeleton. As the child grows, hematopoiesis gradually becomes restricted to the central skeleton (vertebrae, sternum, ribs, pelvis) and proximal long bones. This progression influences the approach to bone marrow examinations throughout childhood.

Common Pediatric Hematological Disorders

Anemias in Children

Anemia represents perhaps the most common hematological condition encountered in pediatrics. Defined as a reduction in hemoglobin or red blood cell count below normal values for age, anemia requires careful evaluation to identify its cause.

Iron Deficiency Anemia

Iron deficiency anemia is the most common nutrition-related deficiency worldwide, particularly affecting toddlers and menstruating adolescents. Clinical presentation may include pallor, fatigue irritability, and in severe cases, pica (craving of non-food substances like ice or soil).

Diagnosis requires evaluation of hemoglobin, hematocrit, mean corpuscular volume (MCV), and iron studies including ferritin, serum iron, and total iron binding capacity. Treatment involves identifying the underlying cause of iron deficiency and providing appropriate iron supplementation, typically 3-6 mg/kg/day of elemental iron divided into two doses.

Hemoglobinopathies

Sickle cell disease and thalassemia represent inherited structural or quantitative defects in hemoglobin synthesis. These conditions are among the most prevalent genetic disorders worldwide and require specialized care throughout the lifespan.

Condition	Pathophysiology	Key Features	Management Principles
Sickle Cell Disease	Structural defect in -globin chain causing polymerization under deoxygenated conditions	Vaso-occlusive crises, pain, anemia, splenic sequestration, susceptibility to infection	Hydroxyurea, prophylactic antibiotics, transfusion therapy, pain management
-Thalassemia Major	Reduced or absent synthesis of -globin chains	Severe anemia appearing in first year of life, hepatosplenomegaly, bony deformities	Regular transfusions, iron chelation therapy, possible hematopoietic stem cell transplantation
-Thalassemia	Reduced synthesis of -globin chains	Severity ranges from silent carrier to hydrops fetalis depending on affected genes	Varies from observation to regular transfusions based on severity

Bleeding and Clotting Disorders

Bleeding disorders in children require careful evaluation because normal ranges for coagulation parameters vary with age. Distinguishing between primary hemostatic disorders (platelet disorders) and secondary hemostatic disorders (coagulation factor disorders) provides a foundation for diagnostic approaches.

Hemophilia A and B (factor VIII and IX deficiency, respectively) are X-linked recessive disorders that present with prolonged bleeding after trauma or surgery, easy bruising, and in severe cases, spontaneous bleeding into joints and muscles. Diagnosis involves factor activity assays, and treatment includes factor replacement products and emerging gene therapy approaches.

Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder characterized by isolated thrombocytopenia with normal red and white blood cell indices. It is the most common cause of thrombocytopenia in childhood. Many cases follow viral infections and typically resolve spontaneously within 6 months. Treatment is based on bleeding symptoms rather than platelet count alone and may include observation, corticosteroids, or IV immunoglobulin.

Diagnostic Approaches in Pediatric Hematology

A systematic approach to hematological assessment in children begins with a thorough history and physical examination, followed by targeted laboratory investigations.

Laboratory Evaluation

Complete blood count (CBC) with differential provides fundamental information about red blood cells, white blood cells, and platelets. However, age-appropriate reference ranges must be used as normal values change significantly during childhood. Peripheral blood smear examination, often overlooked in modern practice, remains invaluable for morphological assessment of blood cells.

Specialized hematological tests include bone marrow examination, flow cytometry for immunophenotyping of blood cells, and molecular genetic testing. Bone marrow aspiration and biopsy are particularly important in diagnosing childhood leukemias, aplastic anemia, and certain storage diseases.

Understanding Childhood Leukemias

Leukemias represent the most common childhood malignancies, accounting for approximately 30% of all pediatric cancers. Acute lymphoblastic leukemia (ALL) accounts for about 75% of childhood leukemias, with acute myelogenous leukemia (AML) comprising most of the remaining cases.

Clinical presentation typically includes symptoms related to bone marrow failure such as anemia, thrombocytopenia causing bleeding, and neutropenia leading to fever or infection. Additional symptoms may include bone pain, lymphadenopathy, hepatosplenomegaly, or meningeal involvement.

Diagnosis requires examination of bone marrow showing greater than 20% leukemic blasts, along with immunophenotyping, cytogenetics, and molecular studies to classify the leukemia and guide treatment decisions.

Special Considerations in Pediatric Hematology

Transfusion Medicine in Children

Blood product transfusion in children requires special consideration of volume, product selection, and possible adverse reactions. Irradiated and leukoreduced products are generally preferred for immunocompromised children and those receiving hematopoietic stem cell transplants. Component dose is typically calculated based on body weight or surface area.

Hematopoietic Stem Cell Transplantation

Hematopoietic stem cell transplantation (HSCT) offers potentially curative therapy for various malignant and non-malignant disorders of the blood. In pediatrics, HSCT is used for high-risk leukemias, relapsed lymphomas, severe aplastic anemia, and numerous genetic disorders including immunodeficiencies, hemoglobinopathies, and metabolic diseases.

Key considerations in pediatric HSCT include donor selection (matched sibling, unrelated donor, haploidentical, or cord blood), conditioning regimens, management of transplant-related complications (graft-versus-host disease, infections, organ toxicity), and long-term follow-up for potential late effects.

Recent Advances and Future Directions

Recent years have witnessed significant advances in pediatric hematology. Genomic technologies have improved our understanding of the molecular basis of many hematological disorders, allowing for more precise diagnoses and targeted therapies.

Novel therapeutic approaches include:

• Gene therapy for hemoglobinopathies such as sickle cell disease and -thalassemia
• Targeted immunotherapies for childhood leukemias, including CAR-T cell therapy
• New anticoagulation protocols adapted for growing children
• Improved supportive care reducing treatment-related complications

Early diagnosis through newborn screening programs has dramatically improved outcomes for conditions like severe combined immunodeficiency and sickle cell disease, allowing for preventive interventions before disease manifestations occur.

Practical Approach to Common Pediatric Hematology Scenarios

Management of Febrile Neutropenia

Fever in a child with neutropenia represents a medical emergency requiring prompt evaluation and empiric antibiotic therapy. This scenario commonly presents in children receiving chemotherapy for malignancies or those with primary immunodeficiencies. Initial assessment should focus on identifying potential infection sources, followed by appropriate cultures and immediate administration of broad-spectrum antibiotics after blood cultures are obtained.

Evaluation of Unexplained Lymphadenopathy

Palpable lymph nodes are common in children, and the vast majority represent benign reactive enlargement to infections. Key features suggesting malignancy include supraclavicular location, size >2 cm, progressive enlargement, associated systemic symptoms (weight loss, night sweats), or firm, fixed, non-tender consistency. Imaging and possible biopsy may be indicated based on concerning features.

Management of ITP

Immune thrombocytopenic purpura in children typically follows a benign course, but management must balance bleeding risks against treatment side effects. Treatment approaches vary internationally but generally reserve intervention for children with significant bleeding or platelet counts below 10,000-20,000/L. Options include observation, corticosteroids, IVIG, and rarely, splenectomy. Patient education regarding avoidance of certain medications and activities with high bleeding risk remains essential.

Conclusion

Pediatric hematology remains a dynamic field requiring integration of clinical expertise with evolving scientific knowledge. Understanding the developmental aspects of children's blood systems, recognizing the spectrum of hematological disorders in pediatric patients, and applying evidence-based diagnostic and therapeutic approaches form the foundation of quality care for children with hematological conditions.

Collaboration between pediatric hematologists, primary care providers, and other specialists ensures comprehensive management addressing both the medical and psychosocial needs of children and their families facing these often challenging diagnoses.